Ligand Pharmaceuticals (LGND) Non-Current Assets (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Non-Current Assets of $666.7 million for Q1 2026, down 8.47% sequentially from $728.4 million in Q4 2025, and up 11.84% YoY from $596.1 million in Q1 2025.
Ligand Pharmaceuticals (LGND) Non-Current Assets (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Non-Current Assets for 17 years, with the latest figure at $666.7 million in Q1 2026.
- Quarterly Non-Current Assets rose 11.84% year-over-year to $666.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 billion (up 12.79% YoY) and the FY2025 annual result came in at $728.4 million, up 19.36% from the prior year.
- Non-Current Assets fell to $666.7 million in Q1 2026 per LGND's latest filing, from $728.4 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $832.5 million in Q2 2022 and troughed at $481.4 million in Q2 2023.
- A 5-year average of $628.5 million and a median of $596.1 million in 2025 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets tumbled 42.18% in 2023, then grew 25.28% in 2024.
- Over 5 years, Non-Current Assets stood at $499.1 million in 2022, then rose by 10.16% to $549.8 million in 2023, then rose by 10.99% to $610.2 million in 2024, then increased by 19.36% to $728.4 million in 2025, then slipped by 8.47% to $666.7 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $666.7 million, $728.4 million, and $722.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 728.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 728.76 Mn |
| Mar 31, 2026 | 666.69 Mn |
| Dec 31, 2025 | 728.37 Mn |
| Sep 30, 2025 | 722.85 Mn |
| Jun 30, 2025 | 595.66 Mn |
| Mar 31, 2025 | 596.12 Mn |
| Dec 31, 2024 | 610.22 Mn |
| Sep 30, 2024 | 645.48 Mn |
| Jun 30, 2024 | 554.15 Mn |
| Mar 31, 2024 | 544.96 Mn |
| Dec 31, 2023 | 549.79 Mn |
| Sep 30, 2023 | 515.23 Mn |
| Jun 30, 2023 | 481.39 Mn |
| Mar 31, 2023 | 482.88 Mn |
| Dec 31, 2022 | 499.07 Mn |
| Sep 30, 2022 | 830.17 Mn |
| Jun 30, 2022 | 832.50 Mn |
| Mar 31, 2022 | 829.12 Mn |
| Dec 31, 2021 | 832.84 Mn |
| Sep 30, 2021 | 841.57 Mn |